Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...

Heart failure is a global health issue. There is a common notion that heart failures can cause permanent damage and can never ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript March 31, 2026 Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2025 ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM ...

New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...

From deli meats and canned soups to pizza and sugary baked goods, many everyday convenience foods are packed with sodium, saturated fat and added sugar.

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today ...

Biocardia () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 30% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...

BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript March 24, 2026 BioCardia, Inc. beats earnings expectations.

The program didn’t have a big impact on BP, but there were lessons for future attempts to address these health disparities.

AI-enhanced single-shot cine MRI produces superior image quality and provides ventricular measurements comparable to ...